MYND — MYND Life Sciences Balance Sheet
0.000.00%
- CA$3.35m
- CA$6.35m
- 18
- 37
- 69
- 36
Annual balance sheet for MYND Life Sciences, fiscal year end - October 31st, CAD millions except per share, conversion factor applied.
2020 October 31st | 2021 October 31st | 2022 October 31st | 2023 October 31st | |
---|---|---|---|---|
Period Length: | — | — | — | — |
Source: | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Cash | ||||
Short Term Investments | ||||
Cash and Short Term Investments | 0 | 1.94 | 0.11 | 0.013 |
Net Total Accounts Receivable | ||||
Net Total Receivables | 0 | 0.098 | 0.128 | 0.778 |
Total Current Assets | 0 | 2.04 | 0.239 | 0.791 |
Gross Property, Plant And Equipment | ||||
Accumulated Depreciation | ||||
Net Property, Plant And Equipment | 0 | 0.328 | 0.115 | 0.006 |
Net Intangible Assets | ||||
Long Term Investments | ||||
Total Assets | 0 | 2.67 | 0.654 | 0.798 |
Accounts Payable | ||||
Payable / Accrued | ||||
Accrued Expenses | ||||
Notes Payable / Short Term Debt | ||||
Current Portion of Long Term Debt / Capital Leases | ||||
Total Other Current Liabilities | ||||
Total Current Liabilities | 0.054 | 0.355 | 4.13 | 5.77 |
Long Term Debt | ||||
Capital Lease Obligations | ||||
Total Long Term Debt | ||||
Total Debt | ||||
Deferred Income Tax | ||||
Total Liabilities | 0.054 | 2.74 | 4.19 | 5.77 |
Common Stock | ||||
Additional Paid In Capital | ||||
Retained Earnings (Accumulated Deficit) | ||||
Other Equity | ||||
Total Equity | -0.054 | -0.068 | -3.53 | -4.98 |
Total Liabilities & Shareholders' Equity | 0 | 2.67 | 0.654 | 0.798 |
Total Common Shares Outstanding |